NICE now recommends Xalkori (crizotinib)for first line treatment of adults with ALK positive advanced non small cell lung cancer- Pfizer
NICE (The National Institute of Care and Health Excellence) now recommends Xalkori (crizotinib) from Pfizer for first line treatment of adults with ALK (anaplastic lymphoma kinase) positive advanced NSCLC after Pfizer tendered a larger discount. The drug was previously available via the UK Cancer Drugs Fund but that source of funding is now being wound up.
Comment:Patients with ALK positive NSCLC develop resistance and new drugs are called for, such as Zykadia (ceritinib) from Novartis and Alecensa (alcetinib) from Roche.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.